

1. A pharmaceutical composition comprising:
 - (a) from about 55% to about 90% by weight of a suspended pharmaceutical active;
 - (b) from about 0.001% to about 1.00% by weight of a suspended stabilizing agent; and
 - (c) from about 9% to about 39% by weight of a solvent;
wherein the composition is encapsulated within a soft gelatin capsule.
2. The composition of Claim 1 wherein the composition comprises from about 58% to about 80% by weight of the suspended pharmaceutical active.
3. The composition of Claim 2 wherein the suspended pharmaceutical active is selected from the group consisting of antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, mucolytics, analgesics, antipyretics, anti-inflammatory agents, local anesthetics, and mixtures thereof.
4. The composition of Claim 1 wherein the composition comprises from about 0.01% to about 1.00% by weight of the suspended stabilizing agent.
5. The composition of Claim 4 wherein the suspended stabilizing agent is selected from the group consisting of phytic acid, disodium salts of ethylene diamine tetraacetic acid, calcium salts of ethylene diamine tetraacetic acid, tetrasodium ethylene diamine tetraacetic acid, sodium hexametaphosphate, di(hydroxyethyl)glycine, 8-hydroxyquinoline, and mixtures thereof.
6. The composition of Claim 5 wherein the suspended stabilizing agent is a disodium salt of ethylene diamine tetraacetic acid.
7. The composition of Claim 1 wherein the composition comprises from about 20% to about 39% by weight of the solvent.
8. The composition of Claim 7 wherein the solvent is selected from the group consisting of polyethylene glycols, polyvinylpyrrolidones, propylene glycols, propylene glycol laureates, glyceryl monolinoleates, glyceryl monooleates, diethylene glycol monoethyl ethers, C₈-C₁₀ triglycerides, fractionated coconut oils, and mixtures thereof.
9. The composition of Claim 8 wherein the solvent is a polyethylene glycol solvent.

10. The composition of Claim 1 wherein the composition further comprises from about 0.1% to about 5% by weight of water.

11. A method of improving the stability of a soft gelatin capsule wherein the method comprises the steps of:

(a) formulating a pharmaceutical composition comprising:

- i) from about 55% to about 90% by weight of a suspended pharmaceutical active;
- ii) from about 0.001% to about 1.00% by weight of a suspended stabilizing agent; and
- iii) from about 9% to about 39% by weight of solvent; and

(b) encapsulating the composition of (a) within the soft gelatin capsule.

12. The method of Claim 11 wherein the suspended pharmaceutical active is selected from the group consisting of antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, mucolytics, analgesics, antipyretics, anti-inflammatory agents, local anesthetics, and mixtures thereof.

13. The method of Claim 11 wherein the suspended stabilizing agent is selected from the group consisting of phytic acid, disodium salts of ethylene diamine tetraacetic acid, calcium salts of ethylene diamine tetraacetic acid, tetrasodium ethylene diamine tetraacetic acid, sodium hexametaphosphate, di(hydroxyethyl)glycine, 8-hydroxyquinoline, and mixtures thereof.

14. The method of Claim 13 wherein the suspended stabilizing agent is a disodium salt of ethylene diamine tetraacetic acid.

15. The method of Claim 11 wherein the solvent is selected from the group consisting of polyethylene glycols, polyvinylpyrrolidones, propylene glycols, propylene glycol laureates, glycetyl monolinoleates, glycetyl monooleates, diethylene glycol monoethyl ethers, C₈-C₁₀ triglycerides, fractionated coconut oils, and mixtures thereof.

16. The method of Claim 15 wherein the solvent is a polyethylene glycol solvent.

17. The method of Claim 11 wherein the pharmaceutical composition further comprises from about 0.1% to about 5% by weight of water.